Innova Captab Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/r15esqmyiykqhb0msgws3sgw.pdf

Key Takeaways


Jammu Plant: Timeline, Economics & Ramp-Up

Lohariwala: "So, the benefit is, like we have earlier also said that the GST benefit. So, we have, like, 12% GST incentive on approximately, say, sale of Rs 650 crores. So, we anticipate a good ramp-up, early ramp-up due to this fiscal benefit."

CDMO Business: The Revenue vs Volume Story

Lohariwala: "The reason for this is, if you understand the way our business operates, for us, we work with our customers on an open costing basis. And the cost of the API directly influence the revenue itself. So, with the declining API prices, our revenues also can take a downward trajectory. However, our margins remain protected."

Sharon Acquisition: Integration & Margin Impact


Capacity & Utilization Across the Base


Margins: Current State & Improvement Path

Srivastava: "We would love, that would be the target we would want to go with."

Market Structure & Competitive Positioning

Lohariwala: "So, all the large players will be benefit from these issues."

Guidance & Commitments

CommitmentSpecificsTimeline
Jammu commercial production startTwo blocks validation-ready by March end; full facility commercializedSeptember quarter (Q2 FY25)
Jammu P&L revenue contributionFull-quarter revenues visibleQ3 FY25 (October-December)
Jammu peak revenue5x-6x asset turn (~₹1,800 crores)Within 5 years of start
Jammu FY26 utilization15-20%FY26
GST threshold achievement₹625 crores domestic turnoverWithin first 3 years of Jammu operations
Blended operating marginAbove 15%FY25-FY26 (aspirational, not firm)
No major capexFocus on scaling Sharon and JammuNext 2-3 years
Sharon and Jammu scale-upRunning on autopilotNext 18 months
CCPS expenses₹1.6 cr/quarter and ₹8.5 cr/9-month charges ceaseAlready ceased (subverted post-Q3)
Interest costOnly Jammu project debt of ₹235 cr at effective 2.5%Going forward

Key Metrics

MetricQ3 FY24
Revenue from operations₹302.5 cr, +25% YoY
Revenue from operations (9M FY24)₹818.7 cr, +19.4% YoY
EBITDA₹47 cr, +27% YoY
EBITDA margin15.5%
EBITDA (9M FY24)₹123.2 cr, vs ₹93.4 cr in 9M FY23
EBITDA margin (9M FY24)15%
Profit after tax₹25 cr, +28% YoY; includes ₹1.6 cr CCPS finance cost impact
Profit after tax (9M FY24)₹65.6 cr, +29.4% YoY
CDMO revenue contribution55% of total revenue
Domestic branded generic contribution17% of total revenue
International branded generic contribution12% of total revenue
Sharon contribution16% of total revenue
Overall exports share24%, vs 10% in Q3 FY23
CDMO revenue (9M FY24)₹484.2 cr
Capacity utilization (9M FY24)45% to 50% blended
Cephalosporin capacity utilization70% to 75%
General block capacity utilization~40%
Order book (ex-Sharon)~₹140–₹150 cr, representing 1.5 months
CCPS one-off finance cost impact₹1.6 cr in Q3; ₹8.5 cr on 9M basis
Jammu project cost~₹350 cr
Jammu project debt₹235 cr, effective interest cost 2.5% after 6% subvention
Jammu peak revenue potential~₹1,800 cr, based on 5x–6x asset turnover
Jammu soft running cost (pre-revenue)~₹2 cr per month including depreciation
IPO net proceeds deployed₹231 cr, 100% of FY24 deployment target
Interest savings expected (full-year FY25)~₹18 cr to ₹20 cr
Sharon FY23 revenue~₹192 cr, at ~50% capacity utilization
Sharon gross conversion margin45% to 50%
GST benefit on Jammu domestic turnover12% reimbursement on ~₹625 cr turnover for full annual benefit of ₹75 cr
Cephalosporin revenue contribution~22% of total
Cephalosporin incremental peak revenue from Jammu₹300–₹400 cr over 3–4 years
Univentis domestic branded generic business~₹200 cr expected this year
Active international registrations189 (16 subject to renewal); 200+ fresh applications in process
In-process product dossiers for exports41
CDMO customers (9M FY24)more than 180